Famciclovir Dosing for Different Diseases
Famciclovir is dosed at 500 mg orally three times daily for 7 days for herpes zoster, 250 mg three times daily for 7-10 days for initial genital herpes, and 125 mg twice daily for 5 days for recurrent genital herpes or herpes labialis in immunocompetent adults. 1, 2, 3
Herpes Zoster (Shingles)
Standard dosing for immunocompetent adults:
- 500 mg orally three times daily for 7 days 4, 5, 6, 7
- Treatment should be initiated within 72 hours of rash onset for maximum benefit 5, 7
- This regimen has been proven to reduce the duration of postherpetic neuralgia (PHN) by approximately 3.5 months in patients ≥50 years old compared to placebo 7
Alternative dosing schedules (shown to be equally effective):
- 750 mg once daily for 7 days 8
- 500 mg twice daily for 7 days 8
- These less frequent regimens may improve compliance while maintaining comparable efficacy to the standard three-times-daily dosing 8
Genital Herpes
Initial Episode
- 250 mg orally three times daily for 7-10 days 1
- Treatment may be extended if healing is incomplete after 10 days 1
- This dosing is equivalent in efficacy to acyclovir regimens for first-episode disease 1
Recurrent Episodes
- 125 mg orally twice daily for 5 days 2, 6, 9
- Treatment must be initiated during prodrome or within 1 day of lesion onset for maximum benefit 3
- Patients should be provided with medication to enable self-initiation at first sign of recurrence 3
Suppressive Therapy
- Famciclovir is effective for chronic suppression of recurrent genital herpes 6, 9
- Consider suppressive therapy for patients with ≥6 recurrences per year 3
- Specific suppressive dosing regimens are not detailed in the provided guidelines, but the medication has demonstrated efficacy in this indication 9
Herpes Labialis (Cold Sores)
- 125 mg orally twice daily for 5 days 2, 3
- Single-dose regimens have been approved and may improve compliance 9
- Treatment must be initiated during prodrome or within 1 day of lesion onset 3
- Critical pitfall: Topical acyclovir is substantially less effective than oral therapy and should not be used 3
Immunocompromised Patients
Important limitation: Famciclovir has limited pediatric data and no specific pediatric formulation available 4
- For adolescents who can tolerate adult dosing: Use standard adult doses 4
- For severe HSV infections in immunocompromised patients: Famciclovir is not the first-line agent; IV acyclovir is preferred for severe disease 2
- Acyclovir-resistant HSV may require IV foscarnet or cidofovir 10
Renal Impairment
- Dose adjustment is mandatory based on creatinine clearance 11
- Famciclovir is predominantly eliminated via the kidneys with a half-life of approximately 2.5 hours 6
- For patients with severe renal impairment who cannot tolerate adjusted oral dosing, IV acyclovir with appropriate dose reduction may be necessary 11
Pediatric Patients
- No pediatric preparation is available, and data on dosing in children are limited 4
- Famciclovir could be used by older children and adolescents able to receive adult dosing 4
- For children <12 years or those unable to swallow tablets, acyclovir remains the preferred alternative at 20 mg/kg orally four times daily (maximum 800 mg/dose) 11
Pregnancy
- No specific recommendations for famciclovir use in pregnancy are provided in the guidelines 1, 10
- The guidelines note that acyclovir has no pattern of adverse pregnancy outcomes reported 10
- For pregnant patients requiring antiviral therapy, consultation with experts is recommended, as acyclovir has more established safety data in pregnancy 10
Key Clinical Considerations
Advantages of famciclovir over acyclovir:
- Better oral bioavailability (77% vs. lower for acyclovir) 6
- Less frequent dosing (three times daily vs. five times daily for acyclovir in herpes zoster) 5, 6, 7
- Longer intracellular half-life of penciclovir triphosphate (7 hours vs. 1 hour for acyclovir) 8
- Comparable efficacy with improved convenience and potentially better compliance 5, 9
Common adverse effects:
- Headache and gastrointestinal upset are most common 6
- Constipation, nausea, and vomiting have been reported 5
- Well-tolerated with a safety profile comparable to acyclovir 5, 9
Critical timing: For all indications, early initiation of therapy (within 72 hours of symptom onset for zoster, within 1 day for recurrent HSV) is essential for optimal outcomes 3, 5, 7